Akero Therapeutics Inc (NASDAQ: AKRO) open the trading on Thursday, with a bit cautious approach as it glided -5.34% to $27.65, before settling in for the price of $29.21 at the close. Taking a more long-term approach, AKRO posted a 52-week range of $11.25-$50.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 0.00%. Meanwhile, its Annual Earning per share during the time was 1.03%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -24.85%. This publicly-traded company’s shares outstanding now amounts to $69.43 million, simultaneously with a float of $58.09 million. The organization now has a market capitalization sitting at $1.92 billion. At the time of writing, stock’s 50-day Moving Average stood at $26.55, while the 200-day Moving Average is $23.87.
Akero Therapeutics Inc (AKRO) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Akero Therapeutics Inc’s current insider ownership accounts for 16.33%, in contrast to 98.57% institutional ownership. According to the most recent insider trade that took place on Oct 01 ’24, this organization’s Chief Operating Officer sold 10,000 shares at the rate of 28.18, making the entire transaction reach 281,770 in total value, affecting insider ownership by 226,286.
Akero Therapeutics Inc (AKRO) Earnings and Revenue Records
Akero Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -24.85% and is forecasted to reach -3.81 in the upcoming year.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Let’s observe the current performance indicators for Akero Therapeutics Inc (AKRO). It’s Quick Ratio in the last reported quarter now stands at 24.89. The Stock has managed to achieve an average true range (ATR) of 1.32.
In the same vein, AKRO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.41, a figure that is expected to reach -0.88 in the next quarter, and analysts are predicting that it will be -3.81 at the market close of one year from today.
Technical Analysis of Akero Therapeutics Inc (AKRO)
[Akero Therapeutics Inc, AKRO] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 47.83% While, its Average True Range was 1.34.
Raw Stochastic average of Akero Therapeutics Inc (AKRO) in the period of the previous 100 days is set at 81.52%, which indicates a major rise in contrast to 38.50% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 41.09% that was lower than 51.12% volatility it exhibited in the past 100-days period.
